3-nitrotyrosine and Hepatopulmonary-Syndrome

It has been postulated that cirrhosis-related lung vasodilatation and the subsequent hepatopulmonary syndrome are partly explained by an increased estradiol level through an enhanced endothelial formation of nitric oxide (NO). In this study, we assessed whether the oestrogen receptor antagonist fulvestrant (F) improves cirrhosis-related lung abnormalities. Cirrhosis was induced in rats by chronic bile duct ligation (CBDL). Four groups were studied: CBDL, CBDL+F, sham, and sham+F. Histological, immunohistochemical, and Western blot analyses were performed on lung samples. In the lung, the endothelial NO synthase and the nitrotyrosine protein expressions were increased in CBDL as compared to sham rats. Both parameters were significantly reduced by fulvestrant in the CBDL rats. Surprisingly, the level of pVASP (an indirect marker of NO formation and action) was decreased in CBDL rats, and fulvestrant had no effect on this parameter. The level of the vascular endothelial growth factor, the diameter of small lung vessels, and the number of macrophages were increased in CBDL lungs in comparison with sham lungs, and these parameters were unaffected by fulvestrant treatment. In conclusion, fulvestrant may not be relevant to improve lung abnormalities in cirrhosis because NO may not be biologically active and because key events contributing to the lung abnormalities are not affected by fulvestrant.

Topics: Animals; Cell Adhesion Molecules; Disease Models, Animal; Estradiol; Estrogen Receptor Antagonists; Fulvestrant; Heme Oxygenase (Decyclizing); Hepatopulmonary Syndrome; Liver Cirrhosis, Biliary; Lung; Macrophages; Male; Microfilament Proteins; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Phosphoproteins; Phosphorylation; Rats, Wistar; Tyrosine; Vascular Endothelial Growth Factor A